An observational study in Coronary Artery Disease, Ischemic Heart Disease (IHD) and Unstable Angina (UA), sponsored by Yonsei University. Recruiting at 4 sites in South Korea. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Yonsei University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Coronary Artery Disease by Yonsei University — 13 open to participants now, 18 under way, none of them phase 3. Coronary Artery Disease · Yonsei University.
Among the 64 studies in Coronary Artery Disease by Yonsei University, this one is the 3rd largest by planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2013, is one of 26 observational ones, reaches primary completion later than 14 of the 17 other live ones, and was the 18th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →13 of the 64 studies in Coronary Artery Disease by Yonsei University are open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
Yonsei University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 540 across the 38 interventional studies, 300 across the 26 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yonsei University is the lead sponsor of 1,421 studies on the registry; 241 are open to participants now.
4 of the studies in Coronary Artery Disease by Yonsei University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05340361Yonsei UniversityEfficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT | 2026-12-31 |
| NCT05936606Yonsei UniversityTailored Anti-platelet Therapy After DES Implantation in High-risk Patients | 2027-05 |
| NCT07235657Yonsei UniversityAI-Assisted Interpretation of Cardiac CT in the Emergency Department | 2027-06 |
| NCT05488665Yonsei UniversityThe COMPLETE Treatment of Bifurcation With Two-stent Techniques: Randomized Comparison of Crush Versus Culotte Technique | 2027-09-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Coronary Artery Disease by Yonsei University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter registry will consecutively enroll patients of all ages undergoing percutaneous coronary intervention (PCI) at four university hospitals in Gangwon Province, Republic of Korea.
The study will describe contemporary clinical, procedural, and medication treatment patterns and assess 1-year clinical outcomes in routine practice.
The primary outcome is patient-oriented composite outcome (POCO), defined as all-cause death, any myocardial infarction, or any repeat revascularization.
No study-specific intervention will be assigned.
This prospective, multicenter, observational registry will consecutively enroll patients of all ages undergoing percutaneous coronary intervention (PCI) at four university hospitals in Gangwon Province, Republic of Korea.
The registry is designed to provide real-world data on the clinical characteristics, angiographic findings, procedural strategies, and pharmacological treatment patterns of patients treated with PCI.
PCI and all subsequent medical care will be performed according to routine clinical practice and at the discretion of the treating physicians. The study will not mandate any diagnostic test, procedural strategy, device, or medication.
Baseline clinical characteristics, cardiovascular risk factors, laboratory findings, angiographic and lesion characteristics, procedural details, in-hospital events, discharge medications, and follow-up clinical outcomes will be prospectively recorded.
For patients undergoing staged PCI during the same hospitalization, information on the initial and subsequent procedures will be recorded separately using dedicated electronic case report forms.
Clinical outcomes will be assessed for 1 year after PCI through review of medical records, outpatient follow-up, and telephone contact.
The primary outcome is patient-oriented composite outcome (POCO), defined as all-cause death, any myocardial infarction, or any repeat revascularization. The registry will evaluate the incidence of POCO and examine its associations with baseline clinical, angiographic, procedural, and treatment-related characteristics.
The criteria were revised on the registry on Oct 7, 2026. See what changed
The study population will consist of consecutive, all-comer patients of any age undergoing percutaneous coronary intervention (PCI) at four participating university hospitals in Gangwon Province, Republic of Korea.
Patients undergoing PCI for any clinical presentation, including chronic coronary syndrome and acute coronary syndrome, will be eligible. There will be no restrictions based on sex, clinical presentation, comorbidity, lesion complexity, or procedural characteristics.
Patients undergoing staged PCI during the same hospitalization will be included. Information on the initial and subsequent procedures will be recorded separately using dedicated electronic case report forms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All consecutively enrolled patients undergoing percutaneous coronary intervention at the participating hospitals. PCI is performed as part of routine clinical care and is not assigned by the study protocol.
Procedure: Percutaneous Coronary Intervention (PCI)
PCI performed as part of routine clinical care; no study-specific procedure is assigned.
Patient-oriented composite outcome (POCO)
A composite of all-cause death, any myocardial infarction, or any repeat revascularization.
Time frame: Within 1 year after the index PCI procedure
Device-oriented composite outcome (DOCO)
A composite of cardiac death, target-vessel myocardial infarction, and clinically indicated target lesion revascularization.
Time frame: Within 1 year after the index PCI procedure
All-cause death
Death from any cause
Time frame: Within 1 year after the index PCI procedure
Cardiovascular death
Death resulting from a cardiovascular cause.
Time frame: Within 1 year after the index PCI procedure
Any myocardial infarction
Any myocardial infarction occurring after the index PCI procedure.
Time frame: Within 1 year after the index PCI procedure
Target-vessel myocardial infarction
Myocardial infarction attributable to the coronary vessel treated during the index PCI procedure.
Time frame: Within 1 year after the index PCI procedure
Clinically indicated Target vessel revascularization (TVR)
Repeat percutaneous coronary intervention or coronary artery bypass grafting of any segment of the target vessel, including the target lesion, when clinically indicated.
Time frame: Within 1 year after the index PCI procedure
Clinically indicated Target vessel revascularization (TVR)
Repeat percutaneous coronary intervention of the target lesion or coronary artery bypass grafting of the target vessel for restenosis or another complication of the target lesion, when clinically indicated. The target lesion includes the treated segment and the 5-mm margins proximal and distal to the implanted stent.
Time frame: Within 1 year after the index PCI procedure
Any repeat revascularization
Any repeat coronary revascularization, including repeat PCI or coronary artery bypass grafting.
Time frame: Within 1 year after the index PCI procedure
Definite or probable stent thrombosis
Definite or probable stent thrombosis according to the Academic Research Consortium criteria.
Time frame: Within 1 year after the index PCI procedure
Major bleeding
Major bleeding defined as Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding.
Time frame: Within 1 year after the index PCI procedure
Plan to share: No — Individual participant data will not be shared because the multicenter registry contains potentially identifiable clinical data, and no data-sharing governance framework has been established among the participating institutions.
Started Jan 2013 (actual). Primary completion is estimated for Dec 2030, 215 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 215 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.